高级检索
当前位置: 首页 > 详情页

Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hosp 4, Tumor Hosp Hebei Prov, Shijiazhuang 050011, Hebei, Peoples R China [2]Inst Genecrab Precis Med, Beijing 100078, Peoples R China [3]Beijing Hosp, Dept Clin Lab, Beijing 100730, Peoples R China [4]Peking Univ, Canc Hosp & Inst, Dept Biochem & Mol Biol, Beijing 100142, Peoples R China
出处:
ISSN:

关键词: cell-free DNA non-small cell lung cancer mutations targeted sequencing

摘要:
Non-small cell lung cancer (NSCLC) is a major public health problem worldwide and leads to a high mortality. NSCLC is always diagnosed in late stages because of its unapparent symptoms. However, cell-free DNA (cfDNA) may serve as a new potential biomarker to detect early stage of non-small cell lung cancer. Here we recruited 10 non-small cell lung cancer patients to obtain fresh tumor tissue, peripheral blood lymphocytes (PBLs), and plasma. CfDNAs from 13 elderly people and 7 middle-age smokers were also extracted as controls. Illumina HiSeq X10 was used to perform next generation sequencing to evaluate differences in mutations among different samples. The result indicated that tumor DNA and its matched plasma cfDNA samples showed high concordance in their mutation patterns. Mutation rate of cfDNA was generally lower than that of tumor tissue andligher than that of PBLs. The plasma cfDNA concentration of NSCLC patients (69.2 +/- 46.9 ng/ml) is significantly higher than that of elderly people (32.5 +/- 5.2 ng/ml, t=2.96, p=0.007) and middle-aged smokers (17.9 9.1 ng/ml, t=2.83, p=0.013). Five mutations (PTEN_c.1375A>G, TP53_c.94G>A, STK11_c.816C>T, PIK3CA_c.1633 G>A, PIK3CA_c.2038G>C) were only identified in NSCLC patients but not in healthy people. Our conclusion was that cfDNA has a similar mutation pattern with its matched tumor tissue DNA. A high concentration of cfDNA and tumor specific mutations in cfDNA may serve as potential non-invasive biomarkers to detect early-stage non-small cell lung cancer.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2016]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2016]版:
Q2 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hosp 4, Tumor Hosp Hebei Prov, Shijiazhuang 050011, Hebei, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Hebei Med Univ, Hosp 4, Tumor Hosp Hebei Prov, Shijiazhuang 050011, Hebei, Peoples R China [*1]The Fourth Hospital of Hebei Medical University/The Tumor Hospital of Hebei Province, Shijiazhuang, Hebei 050011, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39767 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号